Achieve Life Sciences (NASDAQ:ACHV) Issues Earnings Results

Achieve Life Sciences (NASDAQ:ACHV) posted its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($0.36) EPS for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.06), Zacks reports.

Achieve Life Sciences Stock Down 4.6 %

NASDAQ:ACHV opened at $2.92 on Wednesday. The firm has a market capitalization of $100.42 million, a PE ratio of -2.58 and a beta of 1.67. Achieve Life Sciences has a 52 week low of $2.82 and a 52 week high of $5.59. The company has a current ratio of 6.78, a quick ratio of 6.78 and a debt-to-equity ratio of 0.31. The stock has a 50 day moving average of $3.22 and a 200-day moving average of $4.04.

Analysts Set New Price Targets

ACHV has been the topic of a number of recent analyst reports. Rodman & Renshaw began coverage on shares of Achieve Life Sciences in a research note on Thursday, November 14th. They issued a “buy” rating and a $12.00 target price on the stock. RODMAN&RENSHAW upgraded Achieve Life Sciences to a “strong-buy” rating in a research note on Thursday, November 14th. Three research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, Achieve Life Sciences currently has an average rating of “Buy” and an average price target of $15.75.

Achieve Life Sciences Company Profile

Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.